Compound ID | 1738
AR-101
Synonym(s): AerumabTM | Panobacumab
Class: Antibody
| Agent Type: | Natural product; Direct acting; Antibody; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Binds to the O-antigen in the outer membrane lipopolysaccharide |
| Target Pathogen: | Active against Pseudomonas aeruginosa |
| Institute where first reported: | Aimmune Therapeutics |
| Year first mentioned: | 2020 |
| Highest development stage: | Phase 2a |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | panobacumab |
| Citation: | https://www.nature.com/articles/s41429-020-0344-z |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.